A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MEC / mitoxantrone, etoposide, and cytarabine

[Related PubMed/MEDLINE]
Total Number of Papers: 9
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MEC  (>> Co-occurring Abbreviation)
Long Form:   mitoxantrone, etoposide, and cytarabine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. CR, MTD, OS
2018 Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. AML, mTORC1, ORR, P-S6
2016 Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia. AML, DLTs
2013 Monocytic crisis of chronic myeloid leukemia in the era of tyrosine kinase inhibitor. CML
2012 Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. AML
2009 A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. AML, MTD, mTOR
2001 Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. AML, CR, MDR
2000 Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. CR, MDR1
1999 [Acute promyelocytic leukemia with t(11;17)(q23;q21)]. ATRA, CAG